• Home
  • Site Map
  • Privacy Policy
    •

    Zegerid (omeprazole/sodium bicarbonate)

    Expanding the Meaning of Acid Control

  • Acid Control
  • Provide More Options for your Patients
  • Coast-to-Coast Managed Care Coverage
  • Information for Pharmacists
  • Tips and Tools
  • Prescribing Information
  • Sign-up for More Information
  • Consumer Website
    •
    ~90% of ZEGERID claims were approved for payment through October, 2008.3

    View coverage information for your patients with the ZEGERID Managed Care Map

    Print the ZEGERID Savings Coupon and help your patients start saving today!

    It's not just omeprazole. It's ZEGERID.

    Launch the ZEGERID Interactive Program to see why.

    Sign up for more information about ZEGERID and other advances relevant to your practice.

    Proven Nighttime Acid Control

    Study 1

    Nighttime acid reflux disease control chart Nighttime acid reflux disease control 10pm-4am

    A pharmacodynamic study (Katz et al., 2007) evaluating nocturnal gastric acidity with a bedtime QD dose (10 pm) of ZEGERID 40 mg Powder for Oral Suspension, esomeprazole 40 mg capsule, and lansoprazole 30 mg capsule, demonstrated:1*

    • Rapid and continued control of nocturnal gastric pH with ZEGERID compared to bedtime dosing of esomeprazole and lansoprazole⊥

    Study 2

    Nighttime acid reflux disease control 10pm-6am

    Another pharmacodynamic study (Castell et al. 2005) evaluating nighttime gastric acidity with a bedtime QD dose (10 pm) of ZEGERID 40 mg Powder for Oral Suspension vs. an evening QD dose of pantoprazole 40 mg tablets demonstrated:2†

    • ZEGERID obtained greater nighttime acid control compared to pantoprazole as measured by gastric pH>4 during the nighttime hours.

    The correlation of pharmacodynamic data to clinical effect has not been established.

    * Randomized, open-label, 7-day crossover study (N=49) to evaluate 3 proton pump inhibitors (PPIs) on nighttime gastric acidity in patients with nighttime symptoms of GERD.

    ⊥ In this study, lansoprazole was administered at 10 pm on an empty stomach; lansoprazole labeling recommends dosing before eating.

    † Randomized, open-label, 7-day crossover study (N=32) to evaluate 2 PPIs on nighttime gastric acidity. ZEGERID was taken at bedtime on all days; pantoprazole was taken at bedtime on days 1 and 7 and prior to dinner on Days 2 through 6.


    Next page: Critically ill patients

    References
    1. Katz PI, Koch FK, et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharmacol Ther. 2007;25:197-205.
    2. Castell D. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. Expert Opin Pharmacother. 2005;6:2501-2510.
    3. Wolters Kluwer Health Source™ Dynamic Claims™. Note that a portion of these approvals may have been reversed by the patient.

    Please see full prescribing information.

    You can obtain additional information about ZEGERID by writing Santarus directly. To speak to a representative by phone or to report an adverse event, call Santarus' Medical Information Department at 1.888.778.0887, option 2 (M-F, 9:00 am to 7:00 pm, EST).

    Product Description
    ZEGERID contains omeprazole, a proton pump inhibitor (PPI), and sodium bicarbonate, an antacid, which raises the gastric pH and thus protects omeprazole from acid degradation.

    Indications and Dosing for ZEGERID
    ZEGERID is indicated for heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
    (20 mg); for the short-term treatment (4-8 weeks) of erosive esophagitis diagnosed by endoscopy
    (20 mg); for maintenance of healing of erosive esophagitis (20 mg) (controlled studies do not extend beyond 12 months); for short-term treatment (4-8 weeks) of active duodenal ulcer (20 mg); for short-term treatment (4-8 weeks) of active benign gastric ulcer (40 mg); and for reduction of risk of upper gastrointestinal bleeding in critically ill patients (only powder for oral suspension 40 mg; use beyond 14 days has not been evaluated).

    Important Safety Information about ZEGERID
    The most frequently reported adverse events with ZEGERID are headache, diarrhea, and abdominal pain. In 178 critically ill patients treated with ZEGERID Powder for Oral Suspension, adverse events generally reflected the serious, underlying medical condition of the patients, and were similar for patients treated with ZEGERID Powder for Oral Suspension than in those treated with the comparator (acid-controlling) drug. For more information about these and other events, please see Table 13 of the Full Prescribing Information. Symptomatic response to therapy does not preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long term with omeprazole.

    ZEGERID Capsules contain 304 mg of sodium per dose. ZEGERID Powder for Oral Suspension contains 460 mg of sodium per dose. This should be taken into consideration for patients on a sodium-restricted diet.

    Sodium bicarbonate is contraindicated in patients with metabolic alkalosis and hypocalcemia. ZEGERID is contraindicated in patients with known hypersensitivity to any component of the formulation.

    Since both 20 mg and 40 mg ZEGERID contain the same amount of sodium bicarbonate (1100 mg in capsules,
    1680 mg in packets of powder for oral suspension), two 20 mg capsules are not equivalent to, and should not be substituted for, one 40 mg capsule, and two 20 mg packets are not equivalent to, and should not be substituted for, one 40 mg packet.

    © 2009 Santarus, Inc. All rights reserved. 1-ZEG08020

    Use of this site constitutes your acceptance of our Terms of Use and Privacy Policy.